Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PROVE

Financiado

Cerrado

Pathogenic Triggers and Drivers of Venous Thromboembolism Intermittent Hypoxia...

Pathogenic Triggers and Drivers of Venous Thromboembolism Intermittent Hypoxia Intravascular Cells and Extracellular Vesicles Venous thromboembolism (VTE) is a common, deadly condition affecting more than 1 million europeans, with 500.000 related deaths in EU per year. Many risk factors are established, but it is not known what triggers a VTE event, whic... ver más

13/02/2023

NORSK POLARINSTITU...

214K€

Presupuesto del proyecto: 214K€

Líder del proyecto

NORSK POLARINSTITUTT No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-02-13

MSCA-IF-2019: Individual Fellowships

I+D

Cerrada hace 5 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

NORSK POLARINSTITUTT

214.16K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

EUIN2013-50833 GLOBAL OMICS LINKED TO AN INTEGRAL ACTION ON THROMBOSIS 18K€ Cerrado

IMMUNOTHROMBOSIS Cross talk between platelets and immunity implications for... 2M€ Cerrado

T-MEMORE Thrombotic MEMOry Linking a break in tolerance to platelets... 1M€ Cerrado

TICARDIO Thrombo inflammation in cardiovascular disease 4M€ Cerrado

TAPAS TArgeting Platelet Adhesion receptors in thrombosiS 4M€ Cerrado

SYSVASC Systems Biology to Identify Molecular Targets for Vascular D... 8M€ Cerrado

Duración del proyecto: 33 meses Fecha Inicio: 2020-04-24
Fecha Fin: 2023-02-13

Líder del proyecto

NORSK POLARINSTITUTT No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 214K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Venous thromboembolism (VTE) is a common, deadly condition affecting more than 1 million europeans, with 500.000 related deaths in EU per year. Many risk factors are established, but it is not known what triggers a VTE event, which hampers development of predictive and therapeutic measures. Hypoxia is known to play a major role in thrombus formation, but via which mechanisms is unclear. PROVE will be conducted at the university of Tromsø, using state-of-the-art equipment in a world-class thrombosis center of excellence (TREC) to uncover how hypoxia contributes to thrombus formation, with an emphasis on immunology and extracellular vesicles (EVs). TREC is composed of three units, combining epidemiology, clinic, and laboratory research, to conduct interdisciplinary, cutting-edge, research. PROVE will add aspects on immunology and EVs to TREC, two fields with greatly increasing importance in thrombotic research. PROVE will address three research objectives: (i) To unravel processes and pathways triggered by IH in intravascular cells (i.e. endothelial cells, monocytes and platelets); (ii) To define the characteristics and procoagulant activity of cell-specific EVs derived from intravascular cells activated by VTE-associated stimuli including IH, (iii) To comprehensively compare cell-specific EVs isolated from plasma of VTE patients and healthy subjects, towards future development of diagnostic tools and improved treatment regimens. This will be achieved by substantial characterizations and functional test of human cells and blood samples from both healthy individuals, and VTE patients. This will result in powerful data sets from protein expression analysis, and RNA sequencing, but also functional experiments to define effects of hypoxia on coagulation, and initiation of thrombi. The long term goal of PROVE is to improve diagnostic and therapeutic procedures, to reduce the substantial suffering and costs of VTE.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores